The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Pilot trial of physical and cognitive changes related to fall risk in enzalutamide patients with castration-resistant prostate cancer (CRPC).
 
Victor Rodriguez
No Relationships to Disclose
 
Michelle Cameron
No Relationships to Disclose
 
Kerri M. Winters-Stone
No Relationships to Disclose
 
Tomasz M. Beer
Stock and Other Ownership Interests - Arvinas; Salarius Pharmaceuticals
Consulting or Advisory Role - Abbvie; Amgen; Arvinas; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Constellation Pharmaceuticals; Dantari Pharmaceuticals; GlaxoSmithKline; GRAIL; Janssen; Myovant Sciences; Pfizer; Sanofi; Sapience Therapeutics
Research Funding - Alliance Foundation Trials (Inst); Astellas Pharma (Inst); Bayer (Inst); Boehringer Ingelheim (Inst); Corcept Therapeutics (Inst); Endocyte (Inst); Freenome (Inst); GRAIL (Inst); Harpoon Therapeutics (Inst); Janssen Research & Development (Inst); Medivation (Inst); Sotio (Inst); Theraclone Sciences (Inst); Zenith Epigenetics (Inst)
 
Joshi J. Alumkal
Consulting or Advisory Role - Bristol-Myers Squibb/Celgene
Research Funding - Beactica (Inst); Zenith Epigenetics (Inst)
 
Jeremy Paul Cetnar
Consulting or Advisory Role - Istari
 
Rajat Thawani
No Relationships to Disclose
 
Taylor Amery
No Relationships to Disclose
 
Jacqueline Vuky
Research Funding - Agendia (Inst); Arvinas (Inst); Astellas Pharma (Inst); Blueprint Medicines (Inst); Bristol-Myers Squibb (Inst); Clovis Oncology (Inst); Deciphera (Inst); Eisai (Inst); Exelixis (Inst); Fortis (Inst); Genentech (Inst); Ignyta (Inst); Incyte (Inst); Innocrin Pharma (Inst); Lilly (Inst); Loxo (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Polyphor (Inst); Rgenix (Inst)
 
Shawna Bailey
No Relationships to Disclose
 
Julie N Graff
Research Funding - Janssen Oncology (Inst); Medivation (Inst); Merck Sharp & Dohme (Inst); Sanofi (Inst)
Patents, Royalties, Other Intellectual Property - Oncoresponse: Exceptional responders